Liver Drug Eases Worry in Cirrhosis Patients
Adults with compensated MASH cirrhosis reported less worry after 52 weeks of resmetirom in a post hoc trial analysis.
Updated on Nov. 7, 2026 in Diabetes
A post hoc analysis of the MAESTRO-NAFLD-1 phase 3 trial found that 52 weeks of resmetirom 80 mg was associated with reduced worry and improved health distress among patients with compensated MASH cirrhosis. The analysis was presented at The Liver Meeting 2026 in Denver, Colorado, and is most relevant to adults living with this advanced stage of fatty liver disease.
Why it matters
Quality of life is a central concern for people with cirrhosis, yet it is rarely the primary focus of liver treatment trials. These findings suggest that addressing liver fibrosis may also ease the emotional and daily burden patients carry, which matters for how clinicians weigh long-term care.
This post hoc analysis of 160 patients with compensated MASH cirrhosis from the 52-week MAESTRO-NAFLD-1 phase 3 trial measured quality of life using validated questionnaires. Worry scores improved significantly while health distress showed only a non-significant trend, and the analysis was not a prespecified endpoint.
The players
MAESTRO-NAFLD-1
A phase 3 clinical trial program evaluating resmetirom, a liver-targeted therapy, in patients with metabolic dysfunction-associated steatohepatitis (MASH).
US Food and Drug Administration (FDA)
The federal agency that regulates drugs and medical devices in the United States, including approval of resmetirom for noncirrhotic MASH with moderate to advanced fibrosis.
The details
Resmetirom is a liver-targeted medication, and patients in the analysis received 80 mg daily for 52 weeks while questionnaires tracked how they felt over time. Liver stiffness was measured by vibration-controlled transient elastography, and patients whose stiffness fell by at least 25% also reported less bleeding gums and joint pain. Sleep and fatigue were the domains most impaired at baseline, and investigators noted that the emotional and symptom gains were most pronounced in patients with portal hypertension.
Timeline
The analysis was presented at The Liver Meeting 2026 from November 5-9, 2026.
Patients received resmetirom for 52 weeks before quality of life was reassessed.
Health Landscape
Resmetirom is currently FDA-approved only for adults with noncirrhotic MASH and moderate to advanced fibrosis (F2-F3). This data extends the conversation to patients with compensated cirrhosis, a group for whom treatment options and quality-of-life evidence remain limited.
If you have been diagnosed with fatty liver disease that has progressed toward cirrhosis, these findings suggest that treatment may matter for how you feel day to day, not only for liver measurements. It is worth discussing with your doctor whether a liver-focused treatment plan and regular fibrosis monitoring fit your situation.
The takeaway
Quality of life is an important outcome in liver disease, and reducing liver stiffness appears linked to feeling better in several ways. Ask your clinician how your fibrosis is being measured and what symptoms you should track over time.
Further reading
For related context, explore more Diabetes coverage, since metabolic liver disease is closely tied to insulin resistance.
